Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

Author:

Garcia-Campelo Rosario,Arrieta Oscar,Massuti Bartomeu,Rodriguez-Abreu Delvys,Granados Ana Laura Ortega,Majem Margarita,Vicente David,Lianes Pilar,Bosch-Barrera Joaquim,Insa Amelia,Dómine Manuel,Reguart Noemí,Guirado María,Sala María Ángeles,Vázquez-Estevez Sergio,Caro Reyes Bernabé,Drozdowskyj Ana,Verdú Ana,Karachaliou Niki,Molina-Vila Miguel Angel,Rosell Rafael

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Cancer statistics, 2019;Siegel;CA Cancer J. Clin.,2019

2. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J. Clin. Oncol.,2020

3. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival;Lee;J. Natl. Cancer Inst.,2017

4. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3